Skip To Main Content
Robert H Vonderheide on Muck Rack

Robert H Vonderheide

As seen in: Nature, JAMA Oncology, Science Magazine, Cell Reports, The Lancet, Cell Press, Healio, HemOnc Today, Annual Reviews Journal, The Journal of Immunology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robert H

Contact Robert H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

“The Sun Has Come Out”: Major News in Pancreatic Cancer Marks Dawn of a New Era

|
By Robert H Vonderheide
| Oncology News Central Verified
This transcript has been lightly edited for style, space, and clarity. Robert H. Vonderheide, MD, DPhil: Hi, I’m Robert Vonderheide. I’m director of the Abramson Cancer Center at Penn Medicine. Oncology News Central (ONC): Which pancreatic cancer data at the American Society of Clinical Oncology (ASCO) Annual Meeting are you most excited about?
Open in Who Shared Issue with article?

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib : A Secondary Analysis of a Nonrandomized Clinical Trial

|
By Kim A. Reiss, Mingyi Xia, Mwangala P Akamandisa, Kurt D’Andrea, Christopher Lord Verified, Stephen Pettitt, Andrew Tutt, Timothy Brown, Mark O’Hara, Charles Schneider, Ursina Teitelbaum, Ryan Hood, Rashmi Tondon, Robert H Vonderheide, Susan Domchek, Katherine L. Nathanson, Brad Wubbenhorst, Zain Hannan
| JAMA Oncology Verified
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial
Open in Who Shared Issue with article?

Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment

|
By Vivien I. Maltez, Charu Arora, Kyle P. Gribbin, Breanna P. Caruso, Margaret E. Haerr, Rina Sor, Qiaoshi Lian, Katie E Blise, Shamilene Sivagnanam, Rosalie C. Sears, Lisa M. Coussens, Robert H Vonderheide, Ronald N Germain, Katelyn T. Byrne
| Cell Press Verified
Keywords regulatory T cell tumor microenvironment CD40 agonist interferon-γ reprogramming Get full text access Log in, subscribe or purchase for full access. References 1. de Visser, K.E. ∙ Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth Cancer Cell. 2023; 41:374-403 2. Gill, A.L. ∙ Wang, P.H. ∙ Lee, J. ... PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors Sci. Immunol.
Open in Who Shared Issue with article?
See all 24 articles